Trials / Completed
CompletedNCT00358813
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate how subjects with mild or moderate kidney problems process or breakdown the study drug GW679769 in their bodies as compared to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Casopitant | Casopitant oral tablets will be available with a dose of 50 milligrams. |
Timeline
- Start date
- 2006-09-08
- Primary completion
- 2008-08-22
- Completion
- 2008-08-22
- First posted
- 2006-08-01
- Last updated
- 2017-08-04
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00358813. Inclusion in this directory is not an endorsement.